Conduct of Development. Gen-Probe and Chiron shall conduct their respective obligations under the Development Program for each Future Blood Screening Assay in compliance in all material respects with all requirements of applicable laws and regulations and all applicable good laboratory, clinical and manufacturing practices. Gen-Probe and Chiron each shall proceed diligently with their respective obligations under each such Development Program and shall use their respective Commercially Reasonable Efforts to achieve its objectives efficiently and expeditiously. Gen-Probe and Chiron each shall allocate sufficient personnel, equipment, facilities and other resources to each such Development Program to carry out their respective obligations and to accomplish the objectives thereof.
Conduct of Development. During the term of this Agreement, DURA shall use commercially reasonable efforts to (a) conduct the Development on behalf of Xxxxxx Corp. II in a prudent and skillful manner in accordance, in all material respects, with the annual workplan and budget then in effect and applicable laws, ordinances, rules, regulations, orders, licenses and other requirements now or hereafter in effect and (b) diligently execute such annual workplan and budget and report to Xxxxxx Corp. II any significant deviations therefrom in a timely manner. Xxxxxx Corp. II hereby appoints DURA its exclusive agent, for the term of this Agreement, with the sole power and authority to file and prosecute all necessary regulatory applications and permits in DURA's name required to obtain FDA Approval and other regulatory approvals for the Xxxxxx Products. DURA shall, at Xxxxxx Corp. II's expense as described below, furnish all labor, supervision, services, supplies and materials necessary to perform the Development in accordance with the annual workplan and budget then in effect. In addition to its undertakings pursuant to the Technology Agreement, DURA agrees to use commercially reasonable efforts, on behalf of itself, DDSI and Xxxxxx Corp., to attempt to obtain and to sublicense to Xxxxxx Corp. II subject to the terms and conditions of the Technology Agreement, on behalf of and at the expense of Xxxxxx Corp. II but in accordance with Section 2.4 of the Technology Agreement, any patent or technology license or sublicense from any Person, including DURA, DDSI or Xxxxxx Corp., that DURA reasonably determines to be necessary or useful to enable DURA to conduct the Development under this Agreement.
Conduct of Development. Ambit has conducted, or has caused its contractors and consultants to conduct, any and all preclinical and clinical studies related to the CONFIDENTIAL Compounds and Licensed Products in accordance with good laboratory and clinical practice as and where appropriate, and Applicable Law.
Conduct of Development. Gen-Probe shall conduct its obligations under the Development Program for each Initial Clinical Diagnostic Assay in compliance in all material respects with all requirements of applicable laws and regulations and all applicable good laboratory, clinical and manufacturing practices. Gen-Probe shall proceed diligently with its respective obligations under each such Development Program and shall use its Commercially Reasonable Efforts to achieve its objectives efficiently and expeditiously. Gen-Probe shall allocate sufficient personnel, equipment, facilities and other resources to each such Development Program to carry out its obligations and to accomplish the objectives thereof.
Conduct of Development. AND COMMERCIALIZATION OF PRODUCT
Conduct of Development. During the term of this Agreement, CVBT shall use commercially reasonable efforts to (a) conduct the Development on behalf of CDCP in a prudent and skillful manner in accordance, in all material respects, with the work plan then in effect and applicable laws, ordinances, rules, regulations, orders, licenses and other requirements now or hereafter in effect and (b) diligently execute such work plan and report to CDCP any significant deviations therefrom in a timely manner. CDCP hereby appoints CVBT its exclusive agent, for the term of this Agreement, with the sole power and authority to file and prosecute all necessary regulatory applications and permits in CVBT’s name required to obtain FDA and other regulatory approvals for CVBT’s Development efforts. Without limiting the generality of the foregoing sentence, absent specific requirements of the FDA to the contrary, CVBT is authorized by CDCP to conduct FDA trials in CVBT’s name. Using the Available Funds provided by CDCP, CVBT shall furnish all labor, supervision, services, supplies and materials necessary to perform the Development in accordance with the work plan then in effect. In addition, CVBT agrees to use commercially reasonable efforts, on behalf of itself and CDCP, to attempt to obtain and to sublicense any patent or technology license or sublicense from any Person, including CVBT, that CVBT reasonably determines to be necessary or useful to enable CVBT to conduct the Development under this Agreement.
Conduct of Development. Each Party shall perform all Development activities under this Agreement in compliance with all Applicable Law (including GMP, GLP and GCP). In furtherance and not in limitation of the foregoing, RevMed shall use diligent efforts to conduct its activities under each Development Plan in accordance with the terms of such Development Plan (including timelines), as the same may be amended from time to time (and which basis for comparison shall be tolled until any then-contemplated or pending amendments are completed or for the duration of any bona fide dispute between the Parties with respect to a Development Plan or amendment thereto), and this Agreement. If either RevMed agrees or it is determined in accordance with [***] that RevMed has committed a material breach of its obligations under this Section 5.2(b) with respect to any Clinical Trial of a Product, the JSC shall, within [***] after such agreement on or determination of material breach, meet in person or by teleconference to discuss such material breach and specify reasonable actions that RevMed should take to cure such material breach. If RevMed fails to commence within [***] after such discussion occurs such actions recommended by the JSC, or fails to cure any such material breach within [***] after the JSC meets (or such longer timeframe as the JSC decides is necessary to complete the actions specified by the JSC), then Sanofi shall have the right, without prejudice to any other rights or remedies Sanofi may have under this Agreement or otherwise at law or in equity[***]. In such case, RevMed shall, [***], (i) make available [***], (ii) provide [***], (iii) provide [***], and (iv) otherwise provide [***].
Conduct of Development. The Parties will cooperate in the conduct of the activities set forth in the applicable Development Plan, including the preparation of protocols and the development of documents therefor. Both Parties will collaborate to achieve globally aligned regulatory documents and interactions for each Product.
Conduct of Development. All Development activities related to MDV3100 and the Initial MDV3100 Product have been conducted in accordance with Applicable Law in all material respects.
Conduct of Development. Biosite and Merck each shall conduct the Development Program in good scientific manner, and in compliance in all material respects with all requirements of applicable laws and regulations and all applicable good laboratory, clinical and manufacturing practices to attempt to achieve its objectives efficiently and expeditiously. Biosite and Merck each shall proceed diligently with the work set out in the Development Program by using their respective good faith efforts to provide, among others, the following resources:
